Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics is a commercial-stage biopharmaceutical company that discovers, develops, produces and commercializes therapeutics for rare diseases. Its ProCellEx platform uses plant cell-based expression to produce recombinant proteins. The company’s approved enzyme replacement therapies are Elelyso for Gaucher disease and Elfabrio for Fabry disease. Its development programs include PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases, as well as research into antisense oligonucleotide therapies for rare renal indications. Protalix sells Elelyso drug substance to Pfizer for worldwide commercialization outside Brazil and sells the product to Fiocruz for Brazil, where it retains distribution rights. Chiesi holds exclusive global commercialization rights for Elfabrio; Protalix manufactures and sells the product to Chiesi and is eligible for milestone payments under its agreements. The company is headquartered in Hackensack, New Jersey.
No SEC Form 4 filings for $PLX in the last 30 days.
See all $PLX insider activity →Protalix BioTherapeutics reported Q3 2026 revenues of $21.8M, up from $17.7M in 2025, with nine-month revenues at $75.6M. Net income rose to $4.0M from $2.4M year-over-year. The company expects to meet or exceed 2026 revenue guidance of $78.0M-$83.0M. PRX-115 Phase 2 study for uncontrolled gout is on track for 2027 results. Cash reserves were $48.5M as of September 30, 2026.
Protalix BioTherapeutics (PLX) presented data at ACR 2026 showing that higher doses of PRX-115, a treatment for uncontrolled gout, kept plasma uric acid levels below therapeutic targets for up to 85 days. The company believes PRX-115 has best-in-class potential and expects top-line results from the Phase 2 RELEASE study in the second half of 2027.
Protalix (PLX) reported Q2 2026 revenues of $19.9M, up from $15.7M in Q2 2025, driven by higher sales to Chiesi. Net income was $3.8M, or $0.05 per share. The company expects top-line results from its RELEASE study in late 2027 and remains focused on rare renal diseases. Cash reserves totaled $40.7M as of June 30, 2026.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning PLX (Protalix BioTherapeutics, Inc.). Coverage has skewed bullish: 8 bullish, 2 neutral, and 0 bearish.
Recent PLX coverage spans earnings, financial news and corporate actions.
Earnings beat and guidance reaffirmation suggest modest upside.
Positive Phase 1 data may boost investor confidence ahead of Phase 2 results.
Earnings beat expectations with higher revenue and profit, suggesting upside potential.
Near-term trading focus is likely on partner-driven revenue lumpiness, regulatory traction for Elfabrio, and the PRX-115 clinical timeline into 2H 2027.
The filing provides fresh, trade-relevant updates on commercial revenue trajectory, cash runway, and the timing of PRX-115 top-line readout (2H 2027).
AlphAI scores every news story that mentions PLX with an AI model for sentiment and relevance, and aggregates insider trades from Protalix BioTherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Protalix BioTherapeutics reported Q3 2026 revenues of $21.8M, up from $17.7M in 2025, with nine-month revenues at $75.6M. Net income rose to $4.0M from $2.4M year-over-year. The company expects to meet or exceed 2026 revenue guidance of $78.0M-$83.0M. PRX-115 Phase 2 study for uncontrolled gout is on track for 2027 results. Cash reserves were $48.5M as of September 30, 2026.
Protalix BioTherapeutics (PLX) presented data at ACR 2026 showing that higher doses of PRX-115, a treatment for uncontrolled gout, kept plasma uric acid levels below therapeutic targets for up to 85 days. The company believes PRX-115 has best-in-class potential and expects top-line results from the Phase 2 RELEASE study in the second half of 2027.
Protalix (PLX) reported Q2 2026 revenues of $19.9M, up from $15.7M in Q2 2025, driven by higher sales to Chiesi. Net income was $3.8M, or $0.05 per share. The company expects top-line results from its RELEASE study in late 2027 and remains focused on rare renal diseases. Cash reserves totaled $40.7M as of June 30, 2026.
Protalix BioTherapeutics reported Q2 2026 earnings call updates. Revenue growth was driven by higher Elfabrio sales to Chiesi, plus a $25 million milestone recognized in Q1 2026. The firm cited a $2.1 million R&D expense reduction from an ongoing grant, cash of $40.7 million with no debt, and projected Fabry market $3.2B by 2031.
Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT ● Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from
Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 plx-20260625xex10d1.htm EX-10.1 Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN ( Amended and Restated as of June 25, 2026 ) 1. Purposes of the Plan . The purposes of this Plan are to attract and retain the best available per
Protalix BioTherapeutics (PLX) has announced its 2026 annual stockholder meeting to be held on June 25, 2026, in Tel Aviv. Key agenda items include the election of eight directors, a non-binding advisory vote on executive compensation, and the approval of an amended 2006 Stock Incentive Plan to increase the share reserve by 3.5 million to 20,975,171 shares. The company also reported CEO Dror Bashan's 2025 compensation of $1.17 million and outlined change-in-control benefits for executives.
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a negative opinion for Protalix BioTherapeutics, Inc.'s ( NYSE:PLX ) and Chiesi Group's partnered Elfabrio's revised dosing schedule for Fabry disease.
